Dashboard
Manage Tickers

BMRNBIOMARIN PHARMACEUTICAL INC

Nasdaq biomarin.com


$ 80.92 $ -1.26 (-1.53 %)    

Friday, 26-Apr-2024 15:59:59 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 431.01 $ 6.55 (1.54 %)
DIA $ 382.27 $ 1.39 (0.36 %)
SPY $ 508.26 $ 4.77 (0.95 %)
TLT $ 88.26 $ 0.46 (0.52 %)
GLD $ 216.60 $ 0.70 (0.32 %)
$ 80.91
$ 81.69
$ 80.90 x 100
$ 80.94 x 200
$ 80.90 - $ 83.08
$ 76.02 - $ 99.56
2,257,132
na
16.12B
$ 0.68
$ 78.47
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 04-26-2024 03-31-2024 10-Q
2 02-26-2024 12-31-2023 10-K
3 11-02-2023 09-30-2023 10-Q
4 08-02-2023 06-30-2023 10-Q
5 04-28-2023 03-31-2023 10-Q
6 02-27-2023 12-31-2022 10-K
7 10-28-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 04-29-2022 03-31-2022 10-Q
10 02-25-2022 12-31-2021 10-K
11 10-29-2021 09-30-2021 10-Q
12 07-30-2021 06-30-2021 10-Q
13 04-30-2021 03-31-2021 10-Q
14 02-26-2021 12-31-2020 10-K
15 11-06-2020 09-30-2020 10-Q
16 08-05-2020 06-30-2020 10-Q
17 05-01-2020 03-31-2020 10-Q
18 02-27-2020 12-31-2019 10-K
19 10-29-2019 09-30-2019 10-Q
20 08-02-2019 06-30-2019 10-Q
21 04-29-2019 03-31-2019 10-Q
22 02-28-2019 12-31-2018 10-K
23 10-26-2018 09-30-2018 10-Q
24 08-03-2018 06-30-2018 10-Q
25 04-27-2018 03-31-2018 10-Q
26 02-26-2018 12-31-2017 10-K
27 10-31-2017 09-30-2017 10-Q
28 08-02-2017 06-30-2017 10-Q
29 05-04-2017 03-31-2017 10-Q
30 02-27-2017 12-31-2016 10-K
31 11-03-2016 09-30-2016 10-Q
32 08-08-2016 06-30-2016 10-Q
33 05-02-2016 03-31-2016 10-Q
34 02-29-2016 12-31-2015 10-K
35 11-02-2015 09-30-2015 10-Q
36 08-05-2015 06-30-2015 10-Q
37 05-05-2015 03-31-2015 10-Q
38 03-02-2015 12-31-2014 10-K
39 10-28-2014 09-30-2014 10-Q
40 07-31-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

morgan-stanley-maintains-overweight-on-biomarin-pharmaceutical-lowers-price-target-to-112
Morgan Stanley Maintains Overweight on Bio...
04/26/2024 16:39:31

Morgan Stanley analyst Matthew Harrison maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and lowers the pri...

canaccord-genuity-maintains-hold-on-biomarin-pharmaceutical-lowers-price-target-to-89
Canaccord Genuity Maintains Hold on Biomar...
04/26/2024 12:48:23

Canaccord Genuity analyst Whitney Ijem maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Hold and lowers the price targ...

citigroup-maintains-neutral-on-biomarin-pharmaceutical-lowers-price-target-to-91
Citigroup Maintains Neutral on Biomarin Ph...
04/25/2024 22:48:49

Citigroup analyst David Lebovitz maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Neutral and lowers the price target ...

why-caterpillar-shares-are-trading-lower-by-around-7-here-are-other-stocks-moving-in-thursdays-mid-day-session
Why Caterpillar Shares Are Trading Lower B...
04/25/2024 17:57:17

deep-dive-into-biomarin-pharmaceutical-stock-analyst-perspectives-8-ratings
Deep Dive Into Biomarin Pharmaceutical Sto...
04/25/2024 16:01:01

scotiabank-maintains-sector-perform-on-biomarin-pharmaceutical-raises-price-target-to-85
Scotiabank Maintains Sector Perform on Bio...
04/25/2024 15:36:23

Scotiabank analyst George Farmer maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Sector Perform and raises the price ...

cantor-fitzgerald-reiterates-overweight-on-biomarin-pharmaceutical-maintains-110-price-target
Cantor Fitzgerald Reiterates Overweight on...
04/25/2024 14:34:39

Cantor Fitzgerald analyst Olivia Brayer reiterates Biomarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and maintains $11...

wells-fargo-maintains-overweight-on-biomarin-pharmaceutical-raises-price-target-to-110
Wells Fargo Maintains Overweight on Biomar...
04/25/2024 14:17:58

Wells Fargo analyst Mohit Bansal maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price targ...

12-health-care-stocks-moving-in-wednesdays-after-market-session
12 Health Care Stocks Moving In Wednesday'...
04/24/2024 20:31:44

biomarin-pharmaceutical-raises-fy2024-adj-eps-guidance-from-260-280-to-275-295-vs-165-est-affirms-fy2024-sales-guidance-from-270b-280b-vs-277b-est
Biomarin Pharmaceutical Raises FY2024 Adj ...
04/24/2024 20:27:50

2024 Full-Year Financial Guidance (in millions, except % and EPS amounts) (Updated)

biomarin-pharmaceutical-q1-adj-071-may-not-compare-to-034-estimate-sales-64883m-miss-65179m-estimate
Biomarin Pharmaceutical Q1 Adj $0.71 May N...
04/24/2024 20:05:28

Biomarin Pharmaceutical (NASDAQ:BMRN) reported quarterly earnings of $0.71 per share which beat the analyst consensus estimate ...

looking-into-biomarin-pharmaceuticals-recent-short-interest
Looking Into Biomarin Pharmaceutical's Rec...
04/03/2024 18:00:15

new-data-to-be-presented-for-biomarins-voxzogo-in-children-with-hypochondroplasia-and-achondroplasia-at-the-american-college-of-medical-genetics-and-genomics-annual-clinical-genetics-meeting
New Data To Be Presented For BioMarin's VO...
03/12/2024 12:55:16

Investigator-Sponsored Phase 2 Study Demonstrated Positive Results for VOXZOGO in Children with HypochondroplasiaNew Analyses H...

canaccord-genuity-reiterates-hold-on-biomarin-pharmaceutical-maintains-91-price-target
Canaccord Genuity Reiterates Hold on Bioma...
02/29/2024 15:33:38

Canaccord Genuity analyst Whitney Ijem reiterates Biomarin Pharmaceutical (NASDAQ:BMRN) with a Hold and maintains $91 price ...

biomarin-complied-with-a-us-department-of-justice-subpoena-for-documents-on-its-testing-programs-for-vimizim-and-naglazyme-cannot-predict-investigations-outcome-or-its-impact-on-its-business-or-financial-statements
BioMarin Complied With A U.S. Department O...
02/26/2024 18:52:33

https://www.sec.gov/ixviewer/ix.html?doc=/Archives/edgar/data/1048477/000104847724000016/bmrn-20231231.htm 

the-latest-analyst-ratings-for-biomarin-pharmaceutical
The Latest Analyst Ratings For Biomarin Ph...
02/23/2024 18:01:13

cantor-fitzgerald-reiterates-overweight-on-biomarin-pharmaceutical-maintains-100-price-target
Cantor Fitzgerald Reiterates Overweight on...
02/23/2024 17:18:13

Cantor Fitzgerald analyst Olivia Brayer reiterates Biomarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and maintains $10...

rbc-capital-reiterates-sector-perform-on-biomarin-pharmaceutical-maintains-100-price-target
RBC Capital Reiterates Sector Perform on B...
02/23/2024 15:47:03

RBC Capital analyst Luca Issi reiterates Biomarin Pharmaceutical (NASDAQ:BMRN) with a Sector Perform and maintains $100 pric...

recap-biomarin-pharmaceutical-q4-earnings
Recap: Biomarin Pharmaceutical Q4 Earnings
02/22/2024 21:15:56

biomarin-pharmaceutical-q4-2023-adj-eps-049-beats-023-estimate-sales-64620m-beat-63688m-estimate
Biomarin Pharmaceutical Q4 2023 Adj EPS $0...
02/22/2024 21:04:38

Biomarin Pharmaceutical (NASDAQ:BMRN) reported quarterly earnings of $0.49 per share which beat the analyst consensus estimate ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION